Zyns, Vapes and the Very Weird Market for New Nicotine Products

Episode Summary

Executive Summary: The episode explores the rapidly evolving nicotine market, focusing on pouches and gums as alternatives to cigarettes and vaping. Co-founder John Coogan explains Lucy Nicotine’s products, regulatory pathways, manufacturing, and marketing strategy, while the hosts unpack how nicotine culture, FDA rules, and youth vaping shaped today’s market and the rise of disposables like Elf Bar.

Main Topics: Nicotine culture and the rise of oral nicotine (Priority: 5/5): The hosts frame nicotine as a recurring cultural and commercial phenomenon, noting the surge in interest around pouches, gums, and memes tied to Zyn and similar products. Lucy Nicotine’s business model and product strategy (Priority: 5/5): Coogan explains why Lucy entered nicotine, how its gum, lozenges, pouches, and 'breakers' are differentiated, and how the company aims to destigmatize oral nicotine while building a brand moat. FDA regulation and market access barriers (Priority: 5/5): The conversation details the PMTA, MRTP, and drug pathways, emphasizing how difficult and expensive it is to launch new nicotine products legally in the U.S. Juul, youth vaping, and the disposable vape explosion (Priority: 5/5): The episode traces how Juul became a regulatory and cultural scapegoat, and how disposables like Elf Bar/Puff Bar expanded through a gray-market strategy that outpaced enforcement. Manufacturing and supply chain of nicotine pouches (Priority: 4/5): Coogan describes pouch production as relatively simple compared with semiconductors or vapes, while noting that Swedish Match and Sweden play an outsized role in the category. Investor skepticism and vice clauses (Priority: 4/5): The discussion covers the difficulty of raising money for nicotine companies because many VC firms prohibit vice-related investments, despite the category’s scale and profit potential. Politics, culture, and reduced-harm framing (Priority: 4/5): Coogan argues nicotine should be viewed through a harm-reduction lens rather than a partisan one, discussing conservative branding, stigma, and the broader shift away from cigarettes.

Key Arguments: Nicotine products are shifting from cigarettes to oral pouches and gum, which represent a lower-risk continuum of use and a growing business opportunity. Lucy entered nicotine because regulation creates a moat; unlike consumer startups in crowded categories, nicotine has high barriers, slower competition, and more defensible brand power. Nicotine pouches are mostly simple formulations: nicotine plus cellulose, flavorings, moisture agents, and sometimes sweeteners; keeping ingredients minimal helps with FDA scrutiny. The main harm in many vaping incidents was not nicotine itself but additives like vitamin E acetate in illicit cannabis vapes. Launching a new nicotine product legally now is extremely difficult because companies must wait for FDA review before selling and often face years of delay and millions in costs. Juul was heavily constrained because of youth usage and political backlash, but disposable vapes surged by exploiting weak enforcement, imports, front companies, and retail gray zones. The nicotine market remains huge because cigarettes still dominate sales, so even small substitution toward oral products creates large upside. Investors are cautious because vice clauses in LP agreements often exclude nicotine, but the speaker argues these blanket bans are too simplistic and should be judged on harm reduction. Nicotine culture has become more visible and 'bro-y,' but the actual customer base is broader, older, and not confined to social-media meme culture. The future of nicotine likely involves persistent demand rather than disappearance; products will evolve, but human nicotine use is described as 'Lindy.'

Data Points: Stock Movers format: Short audio reports, five minutes or less - Bloomberg promo intro before the Odd Lots episode Lucy founded: 2016 - Hosts note Lucy existed long before the recent Zyn meme boom Nicotine market size in the U.S.: $75 billion - Coogan estimates the total U.S. nicotine market Cigarettes share of U.S. nicotine market: $55 billion / 72% - Coogan says cigarettes remain the dominant category Smokeless nicotine market: $10 billion - Includes oral nicotine and pouches Pouch category size: About $2.5 billion to $3 billion - Coogan describes oral nicotine pouches/gum as a smaller but fast-growing segment E-cigarette and vapor market size: $5 billion - Coogan contrasts vaping with pouches and cigarettes Cigarette market decline: 5% over the last year - Used to argue the cigarette market is shrinking quickly E-cigarette/vapor market decline: About 10% over the last year - Coogan says vaping is declining faster than cigarettes Monthly vape decline: 16% - He says the decline accelerated in the most recent month mentioned Underage vape use before Juul: About 20% - Coogan cites youth tobacco survey data Underage vape use after Juul growth: Almost 40% - He says usage nearly doubled after Juul’s rise Nicorette gum strengths in the U.S.: 2 mg and 4 mg - Coogan compares Lucy’s gum to Nicorette Nicorette gum strength internationally: 6 mg - Used to justify Lucy’s 6 mg gum in the U.S. Lucy gum strength: 6 mg - Company chose a stronger formulation than U.S. Nicorette Zyn product strengths: 3 mg and 6 mg - Referenced as a benchmark in the pouch market Sales growth mentioned for Zyn: Hundreds and hundreds of percent - Hosts describe explosive growth and shortages Disposable vape market ranking: Second largest class of products after cigarettes - Coogan’s framing of the category’s scale Sweden’s health outcome: Lowest lung cancer rates in Europe - Used to support the harm-reduction case for oral nicotine Initial youth tobacco survey age range: 13 to 18 - Coogan describes the NYTS survey process Tobacco age limit in the U.S.: 21 plus - He notes the legal age increase during the anti-vaping crackdown Colorado facility investment by Swedish Match: $600 million - Mentioned as a recent manufacturing expansion PMTA review timing: Potentially 3-5 years or more - Host and guest discuss how long FDA review may take

Pivotal Quotes: "This product contains nicotine. Nicotine is an addictive chemical." — John Coogan: He explains the warning label on Lucy and other tobacco-free nicotine products "The market for meal replacement shakes and protein shakes was not oligopolistic or monopolistic in any way. We actually kind of learned this in a pitch with Peter Thiel... we learned that it was much more important if we were going to be consumer products, entrepreneurs to go into products that had moats." — John Coogan: Coogan contrasts Soylent with Lucy and explains why regulation can be an advantage "The center for tobacco products at the FDA... they have the ability to review PMTAs and issue marketing granted orders or marketing denial orders." — John Coogan: He describes the regulatory gatekeeping that shapes the nicotine industry

Implications: Nicotine is not disappearing; it is migrating into new, more regulated formats. The winners may be companies that combine harm-reduction messaging, brand differentiation, and regulatory patience, while enforcement gaps continue to favor gray-market disposables.